We are Sorry, This Page doesn't Exist
Shire sells cancer drugs to Servier for $2.4 billion as Takeda circles
LONDON (Reuters) - Shire , the London-listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceutical , is selling its oncology business to unlisted French drugmaker Servier for $2.4 billion......»»
Drugmaker Bristol-Myers to buy Celgene for $74 billion
Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion in a cash-and-stock deal, creating a powerhouse that will have several blockbuster cancer drugs......»»
Gilead buys Forty Seven for $4.9 billion to bolster cancer drug pipeline
Gilead Sciences Inc said on Monday it would buy Forty Seven Inc for $4.9 billion in cash, adding an experimental treatment that targets blood cancer to its portfolio of oncology drugs......»»
Gilead just made a $4.9 billion bet on cancer-drug maker Forty Seven
The deal is the latest to add to Gilead's presence in cancer immunotherapy, an approach to treating cancer that harnesses the body's immune system......»»
GlaxoSmithKline CEO expects to get "at least" six drug approvals from the FDA in 2020
GlaxoSmithKline CEO Emma Walmsley told "Mad Money" host Jim Cramer the British drugmaker has received "positive data" for cancer and HIV drugs......»»
J&J bumps up full-year profit view on strength of cancer drugs
Johnson & Johnson on Tuesday boosted its full-year adjusted profit forecast, as multi-billion dollar sales of its cancer drugs Darzalex and Imbruvica helped it beat estimates for third-quarter profit......»»
Why cell therapies are cancer"s next frontier
South San Francisco-based Allogene is taking a different approach to cell therapy for cancer by producing so-called allogenic cell therapies......»»
Pfizer unit to merge with Mylan
Drugmaker Pfizer will spin off its generic drugs business and combine it with Mylan. As Fred Katayama reports, that'll allow Pfizer to focus on its more profitable cancer business......»»
Pfizer to merge generics unit with Mylan; seeks to sharpen cancer focus
Drugmaker Pfizer Inc has agreed to spin off its generic drugs business and combine it with Mylan , a move that leaves Pfizer with more profitable innovative drugs, including cancer drug Ibrance and pneumonia vaccine Prevnar......»»
Factbox: The Galapagos drugs pipeline that has drawn in Gilead
U.S. antiviral drugmaker Gilead Sciences will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV ......»»
Wilmington biopharmaceutical firm developing cancer therapies raises $60M
Prelude Therapeutics, a Wilmington-based biopharmaceutical company taking a new approach to treating cancer, recently closed its $60 million series B financing round. Founded during the summer of 2016, Prelude is focused on discovering and developi.....»»
Pfizer makes $10.6 billion cancer bet in cash deal for Array Biopharma
Pfizer Inc on Monday said it would buy Array Biopharma Inc for $10.64 billion in cash, a deal it hopes will help make it a leader in colon cancer and build up its pipeline of oncology drugs......»»
Pfizer bolsters cancer portfolio with $10.64 billion deal for Array
Pfizer Inc said on Monday it would acquire Array Biopharma Inc for $10.64 billion in cash to beef up its cancer portfolio as it faces rising generic competition for its blockbuster drugs......»»
Pfizer to buy cancer drug developer Array for $10.64 billion
Pfizer Inc said on Monday it would acquire Array Biopharma Inc for $10.64 billion in cash, giving it access to the target's approved drugs for skin cancer and the targeted cancer medicines in its pipeline......»»
Amid IPO rumors, this biotech unicorn taps ex-Juno CEO to lead company
The former site head of Bayer's Berkeley campus is taking over as CEO of Menlo Park, California-based Grail Inc., which has raised close to $2 billion to develop a simple blood test aimed at detecting cancer early. Hans Bishop, who led Seattle-ba.....»»
Amid IPO rumors, this biotech unicorn lands ex-Bayer exec as fourth CEO in 22 months
The former site head of Bayer's Berkeley campus is taking over as CEO of Menlo Park-based Grail Inc., which has raised close to $2 billion to develop a simple blood test aimed at detecting cancer early. Hans Bishop, who led pioneering cancer immuno.....»»
Merck buys Peloton to expand its kidney cancer treatment portfolio
U.S. drugmaker Merck & Co Inc on Tuesday agreed to buy Peloton Therapeutics Inc for $1.05 billion in cash, gaining access to the privately held company's lead kidney cancer drug candidate......»»
Newer drugs fuel AstraZeneca quarterly sales beat
AstraZeneca Plc beat first-quarter sales and earnings expectations on Friday as the British drugmaker benefited from a push into cancer drugs and emerging markets including China......»»
AstraZeneca in cancer drug deal that could pay Daiichi Sankyo up to $6.9 billion
AstraZeneca Plc and Daiichi Sankyo Co Ltd signed a deal to develop and sell Daiichi's cancer drug trastuzumab deruxtecan that could see the British drugmaker pay as much as $6.9 billion to its Japanese partner......»»
AstraZeneca could pay Daiichi Sankyo up to $6.9 billion in cancer drug deal
AstraZeneca Plc and Daiichi Sankyo Co Ltd signed a deal to develop and sell Daiichi's cancer drug trastuzumab deruxtecan that could see the British drugmaker pay as much as $6.9 billion to its Japanese partner......»»